Last updated on June 2019

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk


Brief description of study

Comparison of survival in patients with or without a matched donor at 36 months

Detailed Study Description

Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation.

Patients without a matched donor received the best available treatment. All patients will be followed at least 36 months or until the end of the study.

Clinical Study Identifier: NCT02757989

Find a site near you

Start Over

IUCT-Oncopole

Toulouse, France
  Connect »

CHU Jean Minjoz

Besançon, France
  Connect »

H pital de Brabois

Vandoeuvre les nancy, France
  Connect »

CHU Jean Minjoz

Besançon, France
  Connect »

CHU Estaing

Clermont Ferrand, France
  Connect »

CHSF Gilles de Corbeil

Corbeil-Essonnes, France
  Connect »

CH Le Mans

Le Mans, France
  Connect »

CH Joffre

Perpignan, France
  Connect »

CH Ren Dubos

Pontoise, France
  Connect »

Institut Curie

Saint-Cloud, France
  Connect »

H pital civil

Strasbourg, France
  Connect »

CHU Jean Minjoz

Besançon, France
  Connect »